39 citations,
May 2011 in “European Journal of Clinical Investigation” Hirsutism can be caused by various conditions besides PCOS, and it's important to treat the underlying issue and manage symptoms with medication and cosmetic approaches.
32 citations,
January 2010 in “Dermatology” Combining laser hair removal with topical eflornithine is recommended for better results in treating unwanted facial hair.
30 citations,
October 2014 in “Journal of The American Academy of Dermatology” A team approach is crucial for managing PCOS, with dermatologists playing a key role.
24 citations,
September 2014 in “Drug Delivery” Using microneedles before applying eflornithine cream can make it more effective at stopping hair growth.
18 citations,
February 2016 in “The Journal of Clinical Endocrinology and Metabolism” Advancements in male reproductive medicine are ongoing, but more research and improved treatments are needed in several areas.
18 citations,
June 2010 in “Current medicinal chemistry” Treating hirsutism in women often requires a mix of medications and cosmetic methods for best results.
12 citations,
May 2005 in “Current obstetrics and gynaecology/Current obstetrics & gynaecology” Hirsutism is too much hair growth in women like the pattern in men, often caused by high male hormones, and can be treated with hormone control and hair removal methods.
10 citations,
January 2014 in “Journal of Mid-life Health” Menopause can cause skin issues, and seeing a dermatologist helps.
10 citations,
January 1985 in “Elsevier eBooks” Active oxygen species might be involved in skin tumor growth, but their exact role is unclear.
9 citations,
January 2015 in “Springer eBooks” The document concludes that managing PCOS involves treating symptoms, regulating periods, and reducing health risks, with specific medications for fertility and metabolic issues.
1 citations,
June 2019 in “Innovare journal of medical sciences” Polycystic Ovary Syndrome (PCOS) is a hormonal disorder in women that can cause infertility and other health issues, and it may be improved by treatments that increase insulin sensitivity.
Inhibiting AP-1 changes skin tumor types and affects tumor cell identity.
Inhibiting AP-1 changes skin tumor types and affects tumor cell identity.
Avicennia Marina extract and avicequinone C can reduce hair loss hormone production and increase hair growth factors, suggesting they could be used to treat androgenic alopecia.
January 2016 in “Dermatology Online Journal” Hormonal therapy changes skin and hair in transgender patients, who need better researched dermatologic care.
Hair follicles can be used to quickly assess drug effects in cancer treatment.
29 citations,
July 2013 in “Journal of Investigative Dermatology” UV radiation causes skin cancer, but sunscreens and certain drugs can help prevent it.
6 citations,
September 2012 in “Our Dermatology Online” Retinoids are effective for various skin conditions and hair loss but have serious side effects, so low doses are recommended.
January 2020 in “International Journal of Applied Biology and P” Finasteride treatment for three years changes certain polyamine levels in the blood but not in urine.
165 citations,
June 2007 in “European Journal of Cell Biology” Hair follicle stem cells are key for hair and skin regeneration, can be reprogrammed, and have potential therapeutic uses, but also carry a risk of cancer.
212 citations,
May 2012 in “Genes & Development” Planarian regeneration begins with a specific gene activation caused by injury, essential for healing and tissue regrowth.
115 citations,
January 2001 in “American journal of clinical dermatology” Eflornithine cream effectively reduces women's unwanted facial hair but hair returns if treatment stops.
6 citations,
April 2018 in “Obstetrics, gynaecology and reproductive medicine” Most women with hirsutism have it because of PCOS, and they need long-term treatment including medication and hair removal to improve their condition.
4 citations,
July 2017 in “Medicine” The document concludes that managing PCOS involves lifestyle changes, medication for symptoms, and weight loss for fertility improvement.
3 citations,
March 2021 in “Metabolites” Hair loss causes differ between men and women due to changes in hormone levels and inflammation-related pathways.
May 2006 in “Women's Health Medicine” Excessive hair growth in women, often from high androgen levels, is usually caused by PCOS, and can be treated with hair removal, medication, and possibly weight loss.
71 citations,
May 1996 in “Journal of Investigative Dermatology” The study investigated the role of ornithine decarboxylase (ODC) in hair follicle function using transgenic mice that overexpressed a mutated ODC transgene in hair follicle keratinocytes. These mice experienced normal initial hair growth but lost their hair completely 2-3 weeks after birth, coinciding with the onset of ODC overexpression and the development of follicular cysts. The study found that the ODC inhibitor 2-difluoromethylornithine could prevent hair loss and partially restore normal skin histology if administered early, and it could also reactivate hair growth in mice with complete hair loss. The results suggested that ODC played a crucial regulatory role in mouse hair follicles.
17 citations,
July 2013 in “Amino Acids” Elevated ornithine decarboxylase (ODC) activity in the epidermis was found to promote skin tumor development by recruiting hair follicle bulge stem cells, as demonstrated in ODC-ER transgenic mice. The study showed that inducing ODC activity with 4-hydroxytamoxifen (4OHT) was sufficient to recruit these stem cells in quiescent skin. Although increased ODC activity also led to higher reactive oxygen species (ROS) generation, the use of the polyamine catabolic oxidase inhibitor MDL72527 revealed that ROS generation did not contribute to tumorigenesis. Instead, MDL72527 treatment resulted in a shorter tumor latency, increased tumor burden, and more carcinomas, indicating that the recruitment of bulge stem cells, rather than ROS, played a key role in tumor promotion.
9 citations,
April 2006 in “International Journal of Dermatology” The document explored the potential of α-difluoromethylornithine (DFMO) as a polyamine inhibitor in controlling hair growth and its applications in cancer treatment and chemoprevention. DFMO was studied for its ability to inhibit ornithine decarboxylase, affecting cell growth and differentiation. It showed promise in suppressing tumor growth and metastasis by inducing apoptosis and inhibiting angiogenesis. DFMO was also investigated for its impact on hair growth, potentially altering hair follicle function and fiber composition. However, the document did not provide details on the number of participants in the studies, which is important for evaluating the findings' reliability.
26 citations,
June 2003 in “PubMed” The study investigated the effects of TPA-stimulated polyamine biosynthesis on metastatic squamous cell carcinoma (mSCC) development in protein kinase C epsilon (PKC epsilon) transgenic mice. It was found that TPA treatment significantly increased epidermal ornithine decarboxylase (ODC) activity and putrescine levels in these mice compared to wild-type littermates. The development of mSCC was completely prevented by administering alpha-difluoromethylornithine (DFMO), an ODC inhibitor, in the drinking water during TPA promotion. However, this treatment resulted in marked hair loss and a decrease in intact hair follicles in the transgenic mice. The findings suggested a link between TPA-induced ODC activity, putrescine accumulation, hair follicle maintenance, and mSCC development, with the observed hair loss being a novel side effect not previously reported in other cancer prevention models.